VBL Therapeutics welcomes Alison Finger and Michael Rice to its Board of Directors

– ISRAEL, Modiin –  VBL Therapeutics (Nasdaq: VBLT) today announced the appointments of Alison Finger and Michael Rice to its Board of Directors, effective July 7, 2021.

“We are pleased to welcome Alison and Michael as the newest members of our Board of Directors,” said Board Chairman, Dr. Bennett Shapiro. “Alison’s extensive experience commercializing products globally at bluebird bio and Bristol-Myers Squibb and Michael’s expertise in healthcare capital markets will be invaluable to us as we approach disclosure of topline data from the OVAL clinical trial of VB-111 in platinum-resistant ovarian cancer and if successful, planning and execution of our strategic and operational objectives to bring VB-111 to patients who would benefit from it.”

About Alison Finger

Ms. Finger has nearly three decades of biotech and pharmaceutical leadership experience building and optimizing brands and portfolios in the areas of genetic medicine, cell therapy, oncology, neurology, virology, and metabolic. She has commercialized products in the U.S., Europe, Asia, and other geographies. Most recently, Ms. Finger was Chief Commercial Officer at bluebird bio, where she built the commercial infrastructure for Europe and the U.S. in advance of bluebird’s first gene and cell therapy product launches. Before bluebird, Ms. Finger spent 21 years at Bristol-Myers Squibb leading the hematology/oncology, neurology, and virology franchises. In these roles, she led portfolio planning, brand, and franchise commercial strategy, and supported Research and Development and Corporate Business Development decisions. Ms. Finger also served as Managing Director of BMS Australia/New Zealand and has managed country, regional, and global P&Ls. Previously, she was chair of the Alliance for Regenerative Medicine Gene Therapy Section and served on the Executive Board of the Alliance for Regenerative Medicine Foundation. She also was a member of the board for The Medicines Australia Industry Association and a member of the Pharmaceutical Strategic Working Group for the Australia Senator for Industry and Innovation.

Ms. Finger earned her B.A. from St. Lawrence University and an M.B.A. from Duke University’s Fuqua School of Business.

About Michael Rice

Mr. Rice has deep experience in portfolio management, investment banking, and capital markets. He is a Founding Partner at LifeSci Partners. Before founding LifeSci, Michael was the co-head of Health Care Investment Banking at Canaccord Adams, where he was involved in debt and equity financing. Mr. Rice was also a Managing Director at Think Equity Partners, where he was responsible for managing Healthcare Capital Markets, which included structuring and executing numerous transactions. Before that, he served as a Managing Director at Bank of America serving large hedge funds and private equity healthcare funds while working closely with Investment Banking. Previously, he was a Managing Director at JP Morgan/Hambrecht & Quist.

He graduated from the University of Maryland and currently sits on the board of 9 Meters Biopharma Inc.

About VBL Therapeutics

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications. VBL Therapeutics has developed three platform technologies: a gene-therapy-based technology for targeting newly formed blood vessels with a focus on cancer, an antibody-based technology targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the Lecinoxoids, a family of small-molecules for immune-related indications. VBL Therapeutics’s lead oncology product candidate, ofranergene obadenovec (VB-111), is an investigational, first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. VB-111 is currently being studied in a VBL Therapeutics-sponsored Phase 3 potential registration trial for platinum-resistant ovarian cancer.

For more information: https://www.vblrx.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team